SOUTH SAN FRANCISCO, Calif., April 25 /PRNewswire-FirstCall/ -- Renovis, Inc. (Nasdaq: RNVS), today announced that PROXY Governance, Inc. and Egan-Jones Proxy Services have joined ISS/Risk Metrics and Glass Lewis & Co. in recommending that Renovis stockholders vote "FOR" the merger agreement with Evotec AG (Frankfurt Stock Exchange: EVT) at the Special Meeting of Stockholders scheduled for May 1, 2008. In the proposed merger, each share of Renovis common stock will be converted into the right to receive American Depositary Share (ADSs) of Evotec representing 1.0542 Evotec ordinary shares.
With these recommendations, all four leading independent proxy advisory firms have recommended that Renovis stockholders support the transaction with Evotec.
The Board of Directors of Renovis unanimously recommends that stockholders vote "FOR" the approval and adoption of the agreement and plan of merger, and the approval of the merger and related transactions as described in the proxy statement/prospectus.
The company encourages all stockholders to vote their shares promptly by phone, Internet, or by mailing their proxy card, and to contact MacKenzie Partners at 800/322-2885 or collect at 212/929-5500 if they have any questions or need any assistance in voting their shares.
Renovis is a biopharmaceutical company focused on the discovery and
development of drugs for major medical needs in the areas of neurological
and inflammatory diseases. The Company's proprietary research programs
focus on the purinergic receptors, P2X3 and P2X7, for the potential
treatment of pain and inflammatory diseases. In addition, Renovis has a
worldwide collaboration and license agreement with Pfizer to research,
develop and com
|SOURCE Renovis, Inc.|
Copyright©2008 PR Newswire.
All rights reserved